INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Grant or awardVerified data

Cummings Keith Lamont reported PLRX

Chief Financial Officer · PLIANT THERAPEUTICS, INC. · PLIANT THERAPEUTICS, INC. — Stock Option (Right to Buy)

Side
A
Value
—
Shares
400.0K
Price
—
Executed
Jan 22, 2026
Disclosed
Jan 26, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jan 22 executedJan 26, 2026 disclosed

PLRX · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
5/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · new position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · PLRX

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    5
    KM
    Kuo MinnieChief Operating Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Grant or award
    		A—
    300.0K sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    5
    CL
    Cheung LilyChief Human Resource Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Grant or award
    		A—
    300.0K sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    5
    CB
    Coulie BernardDirector, President and CEO
    PLRXPLIANT THERAPEUTICS, INC.
    Grant or award
    		A—
    1.23M sh
    		Jan 22, 2026Jan 26, 2026
    traded Jan 22, 2026
    		+4dSEC FORM 4

    Evidence

    24
    CL
    Cummings Keith LamontChief Financial Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$31K
    24.0K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    24
    CL
    Cheung LilyChief Human Resource Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$9,644
    7,534 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    27
    CB
    Coulie BernardDirector, President and CEO
    PLRXPLIANT THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$114K
    89.4K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    24
    KM
    Kuo MinnieChief Operating Officer
    PLRXPLIANT THERAPEUTICS, INC.
    Open-market sale · 10b5-1 plan
    		SELL$8,854
    6,917 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001746473-26-000020
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 22, 2026
    Published
    Jan 26, 2026
    Ingested by INSIDER
    Nov 5, 04:20 UTC
    Last re-read
    Nov 5, 04:20 UTC

    Extracted facts

    Filer
    Cummings Keith Lamont
    Role
    Chief Financial Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    PLIANT THERAPEUTICS, INC. — Stock Option (Right to Buy)
    Ticker
    PLRX
    Shares
    400.0K
    Price per share
    $0
    Execution date (reported)
    Jan 22, 2026
    Owned after transaction
    400.0K shares
    Days from execution to publication
    4

    What this establishes

    Cummings Keith Lamont filed this Form 4 reporting a grant or award of PLRX on Jan 22, 2026. It became public on Jan 26, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Financial Officer
    Cummings Keith Lamontcik:0001809204
    Issuer
    PLIANT THERAPEUTICS, INC.cik:0001746473

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.